Company Profile
Curacle co.,ltd., a bio-venture business provides the research and development of drugs for intractable vascular and metabolic diseases due to aging. The company's products in pipeline include CU06, a next-generation oral therapy, which completed phase 2a clinical trial for the treatment of diabetic macular edema.
Its portfolio also includes CU01, which completed Phase 2b clinical trial for Nrf2 activation and inhibition of TGF- ร/Smad signaling, MT-101, a fully humanized Tie2 agonist antibody for the treatment of renal diseases, and MT-103, a bispecific antibody combining Tie2 agonist and anti-VEGF functions for the treatment of wAMD. It also develops MT-105 for the treatment of irritable bowel diseases.
Its portfolio also includes MT-201, a non-bleeding anti-thrombotic antibody targeting PD-X, MT-202, a dual-mechanism therapy combining PD-X inhibition and Tie2 agonism for the treatment of acute ischemic stroke and heart failure with preserved ejection fraction, CU71, a next-generation neurovascular stabilizer for the treatment of alzheimer's disease, and CP01-R01, a first oral endothelial stabilizerยbased candidate for companion animal CKD therapy.
Additionally, it develops SOLVADYS, proprietary oral small-molecule platform for the treatment of endothelial dysfunction EAGLES, a flagship platform of Maptics for next-generation biologics. curacle co.,ltd. was incorporated in 2016 and is headquartered in Seoul, South Korea.